Royal Society of Chemistry

Maria Antonietta Loi Appointed Next Editor-in-Chief of Applied Physics Letters

Retrieved on: 
Thursday, April 11, 2024
University, American Institute of Physics, National Research Council, Physics, Light-emitting diode, American Physical Society, Royal Society of Chemistry, APL, Applied Physics Letters, Semiconductor, Johannes Kepler University Linz, History, Engineering, Science, Optoelectronics, AIP, University of Cagliari, Publishing, Book

MELVILLE, N.Y., April 11, 2024 /PRNewswire/ -- AIP Publishing and Applied Physics Letters (APL) are pleased to announce Prof. Maria Antonietta Loi's appointment to APL editor-in-chief.

Key Points: 
  • MELVILLE, N.Y., April 11, 2024 /PRNewswire/ -- AIP Publishing and Applied Physics Letters (APL) are pleased to announce Prof. Maria Antonietta Loi's appointment to APL editor-in-chief.
  • APL has played a pivotal role in the history of applied physics over the last sixty years; generations of scientists have been educated reading APL papers," said Prof. Loi.
  • That tradition is one that Prof Loi intends to carry on to the next generation of researchers advancing applied physics.
  • "Prof. Loi has established herself as one of her field's brightest stars, and we are delighted she will be leading Applied Physics Letters," said AIP Publishing Chief Publishing Officer Penelope Lewis.

Lifezone Metals Announces Two-Phased Development Plan for the Kabanga Nickel Project in Tanzania

Retrieved on: 
Monday, February 26, 2024
Environment, Other Energy, Engineering, Alternative Energy, Manufacturing, Energy, Mining, Minerals, Natural Resources, Science, Other Science, Nickel, Doctor of Science, Copper, Royal Society of Chemistry, Doctor of Philosophy, Multimedia, News, Metallurgy, Safety, LZM, Kabanga Nickel Project, Cobalt, Institute for Colored Youth, Environmental impact assessment, Composite, Metal, Rare-earth element

Lifezone Metals has determined that a two-phase development plan for its Kabanga Nickel Project will form the base case of the Definitive Feasibility Study.

Key Points: 
  • Lifezone Metals has determined that a two-phase development plan for its Kabanga Nickel Project will form the base case of the Definitive Feasibility Study.
  • The Company continues to collaborate closely with its project partner on this two-phased development plan, as well as numerous other Definitive Feasibility Study work streams.
  • Lifezone Metals is working to evolve and integrate sustainability across Project planning, implementation and in-country operational readiness.
  • Ongoing refinement of the development plan and metallurgical testing is aimed at maximizing the net present value of the Project while optimizing capital outlays.

Cipher Neutron Appoints Dr. Bruno Pollet to its Advisory Board

Retrieved on: 
Wednesday, January 31, 2024
Engineering, Other Energy, Environment, Manufacturing, Green Technology, Energy, Neutron, Hydrogen, Multimedia, IOP, Green hydrogen, Corporation, Engineer, TCP, Natural gas, Book, Advisory board, Transition, Committee, Coventry University, Royal Society of Chemistry, Council, Springer, Cipher, Greenhouse gas, Electrolysis, IEA, ResearchGate, International Association, Sustainable development, Publication, Experiential learning, Water, United, Natural Resources, UNECE, Doctor of Philosophy, Energy transition, Greenhouse gas emissions, Research, House, International Energy Agency, AEM, Innergex Renewable Energy, Commons

Canadian company Cipher Neutron Inc. (“Cipher Neutron” or “CN”) is very pleased to announce that it has appointed the renowned Dr. Bruno Pollet to its Advisory Board.

Key Points: 
  • Canadian company Cipher Neutron Inc. (“Cipher Neutron” or “CN”) is very pleased to announce that it has appointed the renowned Dr. Bruno Pollet to its Advisory Board.
  • Dr. Bruno Pollet is a member of the Council of Engineers for the Energy Transition (CEET): An Independent Advisory Council to the United Nations’ Secretary-General, and a CEET Hydrogen Task Force leader.
  • Dr. Bruno G. Pollet, PhD in Physical Chemistry in the field of Electrochemistry and Advisory Board member of Cipher Neutron stated, “In Canada and abroad, Cipher Neutron’s AEM Electrolyser Technology is a hydrogen industry accomplishment to be very proud of.
  • I look forward to applying my years of experience as an advisor to the great team at Cipher Neutron.”
    Gurjant Randhawa, M.Eng., P.Eng., President and CEO of Cipher Neutron, stated, “Cipher Neutron is very pleased to welcome Dr. Pollet to its growing Advisory Board.

Green Science Alliance Developed Plant Based Vegan Gel Nails

Retrieved on: 
Wednesday, December 13, 2023
Petroleum, CO2, Biomass, Soil, UV, Royal Society of Chemistry, LED, Cosmetics

KAWANISHI-CITY, Hyogo Prefecture, Dec. 13, 2023 /PRNewswire/ -- Dr. Hirotoshi Umemoto, Mr. Hideki Konishi and Dr. Ryohei Mori at Green Science Alliance Co., Ltd. developed plant based vegan gel nail "with Re:soil" trademark.

Key Points: 
  • KAWANISHI-CITY, Hyogo Prefecture, Dec. 13, 2023 /PRNewswire/ -- Dr. Hirotoshi Umemoto, Mr. Hideki Konishi and Dr. Ryohei Mori at Green Science Alliance Co., Ltd. developed plant based vegan gel nail "with Re:soil" trademark.
  • This time, gel nails were made from plant so that they can be called vegan gel nails.
  • Developed vegan gel nails can be cured just like commercial petroleum derived gel nails by UV or LED lamp.
  • They designed their plant based vegan artificial nail tips with this vegan gel nails and it is the first time in the world to make such designed nail tips in which all components were made of plant derived materials (plant derived gel nails and plant derived artificial nail tips).

Giga Metals Engages The Armchair Trader

Retrieved on: 
Wednesday, November 1, 2023
Armchair, CDN, OTCQX, Royal Society of Chemistry, News, Royal Society, FSE, Furniture

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Mark Jarvis, CEO of Giga Metals Corp. (TSX.V: GIGA, OTCQX: GIGGF, FSE: BRR2) announced today that the Company has entered into a corporate awareness agreement with The Armchair Trader, headquartered in London.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Mark Jarvis, CEO of Giga Metals Corp. (TSX.V: GIGA, OTCQX: GIGGF, FSE: BRR2) announced today that the Company has entered into a corporate awareness agreement with The Armchair Trader, headquartered in London.
  • The Armchair Trader will provide advertising to increase awareness of the issuer through editorial content, interviews, events, podcasts and news coverage.
  • The Armchair Trader does not provide Investor Relations or Market Making services.
  • The Armchair Trader currently holds no securities in Giga Metals.

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

Retrieved on: 
Thursday, September 14, 2023
MSD, GABAA receptor positive allosteric modulator, Ion channel, Human, Society, Central nervous system, PAM, Royal Society of Chemistry, Pharmacokinetics, Research, RSC, Society of Chemical Industry, Patient, Chemical industry, DSM-IV codes, Acetylcholine, Merck, Merck & Co., SCI, PAMS, BioScience Research Collaborative, Pharmaceutical industry, Bionomics

MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375.

Key Points: 
  • MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375.
  • Under the 2014 exclusive Research Collaboration and License Agreement, MSD funds all research and clinical development, and worldwide commercialization of any resulting products.
  • This collaboration generated payments of $20M upfront and $10M for a Phase 1 milestone.
  • Bionomics is eligible to receive up to $465M in additional milestone payments for certain development and commercial milestones plus royalties on net sales of licensed drugs.

Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board

Retrieved on: 
Tuesday, March 28, 2023
Popular Mechanics, Medicine, Society, Broad Institute, Canadian Academy of Engineering, European Society for Biomaterials, Royal Society of Chemistry, Boston Business Journal, Research, Messenger, Biology, Harvard Medical School, MIT Technology Review, National academy, Biomedicine, Patient, ERNA, Outline of health sciences, National Academy of Inventors, Boston (magazine), Hospital, Applied science, BMES, Biomedical Engineering Society, American Institute, Distinguishing, Mechanics, Vaccine, Pharmaceutical industry, Eterna, Engineering, Anesthesia, Brigham

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Jeff Karp, Ph.D. to Eterna’s Scientific Advisory Board.

Key Points: 
  • Matt Angel, Ph.D., Chief Executive Officer and President of Eterna, commented, “Jeff is a world-class expert in drug delivery and cell therapeutics with a successful track record as an entrepreneur whose innovations have spurred numerous biomedical products and companies.
  • Several technologies developed in his lab have led to multiple products currently in development or on the market, and to the launch of ten companies.
  • Most recently, he received the Clemson Award for Applied Research, the highest award for innovation from the Society for Biomaterials.
  • His work has been selected by Popular Mechanics as one of the Top 20 New Biotech Breakthroughs that Will Change Medicine.

STORM Therapeutics Expands R&D Leadership Team

Retrieved on: 
Tuesday, January 10, 2023
Storm, Cancer, Clinical trial, Cambridge Crystallographic Data Centre, Celltech, CMC, Computational chemistry, Drug discovery, Therapy, University of Cambridge, University, UCB, Enzyme, RME, Trial of the century, Royal Society, Patient, Ophthalmology, Neurology, Royal Society of Chemistry, Columbia University, Medicinal chemistry, UCLA, METTL3, Patent, Bachelor of Science, Senior, Doctor of Philosophy, RNA, Nobel Prize, DMPK, Pharmaceutical industry, Chemistry

Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.

Key Points: 
  • Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.
  • Newly promoted Vice President of Medicinal Chemistry, Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "I am delighted to welcome Matthew to the leadership team at STORM.
  • Matthew Fyfe, Senior Vice President of STORM Therapeutics, commented: "I am excited to be joining this strong and experienced drug discovery and development team.

STORM Therapeutics Expands R&D Leadership Team

Retrieved on: 
Tuesday, January 10, 2023
Storm, Cancer, Clinical trial, Cambridge Crystallographic Data Centre, Celltech, CMC, Computational chemistry, Drug discovery, Therapy, University of Cambridge, University, UCB, Enzyme, RME, Trial of the century, Royal Society, Patient, Ophthalmology, Neurology, Royal Society of Chemistry, Columbia University, Medicinal chemistry, UCLA, METTL3, Patent, Bachelor of Science, Senior, Doctor of Philosophy, RNA, Nobel Prize, DMPK, Pharmaceutical industry, Chemistry

Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.

Key Points: 
  • Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.
  • Newly promoted Vice President of Medicinal Chemistry, Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "I am delighted to welcome Matthew to the leadership team at STORM.
  • Matthew Fyfe, Senior Vice President of STORM Therapeutics, commented: "I am excited to be joining this strong and experienced drug discovery and development team.

K. Barry Sharpless, 1959 Alumnus of Friends' Central School, Wins Second Nobel Prize

Retrieved on: 
Wednesday, October 12, 2022
Chemistry World, Marine biology, Technology, The Philadelphia Inquirer, Friends' Central School, University of Copenhagen Faculty of Science, National, American Chemical Society, Massachusetts Institute of Technology School of Science, Central School, Multimedia, Science, History, University, Student, Lego, Scripps Research, Nobel Prize in Chemistry, Harvard University, Learning, Royal Society of Chemistry, Friends, Central, Copper, Faculty, Royal Society, Interview, Quakers, Manasquan River, Sharpless, Dartmouth College, Nobel, Copenhagen, Nobel Prize, Stanford University, DNA, Massachusetts Institute of Technology, Click chemistry, National academy, Pharmaceutical industry, Tutoring, Chemistry

WYNNEWOOD, Pa., Oct. 7, 2022 /PRNewswire/ -- Only five scientists in history have won a Nobel prize twice, and among those five is K. Barry Sharpless, a Class of 1959 alumnus of Friends' Central School in Wynnewood, Pennsylvania.

Key Points: 
  • WYNNEWOOD, Pa., Oct. 7, 2022 /PRNewswire/ -- Only five scientists in history have won a Nobel prize twice, and among those five is K. Barry Sharpless, a Class of 1959 alumnus of Friends' Central School in Wynnewood, Pennsylvania.
  • On October 5, the 2022 Nobel prize in chemistry was awarded to scientists K. Barry Sharpless, Carolyn Bertozzi, at Stanford University, and Morten Meldal, at the University of Copenhagen.
  • The three were recognized for devising a method to "click" molecules together that has been described as working like "molecular Lego."
  • K. Barry Sharpless won his first Nobel prize in chemistry in 2001 for his work on catalyzed oxidation reactions, another type of chemical reaction used to produce drugs.